Featured Article
A new treatment that combines a personalized dendritic cell vaccine with the immune-boosting substance poly-ICLC has been shown to enhance the immune response and activity of T cells in patients with malignant glioma.
Precision Oncology Today
Magazine
Beginning a New Era of Precision Alzheimer’s Therapeutics
Alzheimer’s is a disease associated with aging and impacts almost seven million people in the U.S. over the age of 65, with women and Black or Hispanic populations disproportionately affected by the condition. Finding an effective treatment for Alzheimer’s disease has proved to be a long and difficult quest.
5 Startups With Proteomics Potential Attracting Investor Cash
Investor appetite is growing for startups that can make proteomics faster, cheaper, and more informative for use in precision medicine. Here are five proteomics...
Trending on Inside Precision Medicine
Takeda Signs Deal Worth $2.2 Billion with AC Immune for Alzheimer’s Vaccine
AC Immune has signed a major deal with Japanese big pharma Takeda with a view to getting its amyloid-beta Alzheimer's vaccine to the market.
Ultra-Low Energy MRI Shows Its Potential
A cheaper, safer, low-energy magnetic resonance imaging (MRI) scanner could become a powerful point-of-care tool and offer accessible, affordable screening, especially in low- to middle-income countries.
Personal Vaccine Combined with Immune-Boosting Agent Improves Treatment of Malignant Glioma
A new treatment that combines a personalized dendritic cell vaccine with the immune-boosting substance poly-ICLC has been shown to enhance the immune response and activity of T cells in patients with malignant glioma.
